Pharmaceutical Technology

APRIL 13, 2023

ImaginAb will be responsible for licensing and supplying the clinical doses of 89Zr crefmirlimab berdoxam, its investigational CD8 ImmunoPET tracer, to Leucid Bio. Biotechnology company ImaginAb has entered into a new non-exclusive licence and supply agreement with Leucid Bio for CD8 ImmunoPET technology.

Licensing 130

Licensing Licensing Gene Therapy Gene 130

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 20, 2023

Empowering of the Central Drugs Standard Control Organisation (CDSCO) through centralisation of drug licensing may not be the path to improve the quality of drugs manufactured in the country both for domestic and international markets, says SME Pharma Industries Confederation (SPIC), the apex organisation of small and medium pharma industries in the (..)

Licensing 149

Licensing Licensing Drugs Manufacturing 149

Pharmaceutical Technology

APRIL 25, 2023

German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology. The therapy candidate is currently under evaluation in the Phase l LuMIERE clinical trial.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Pharmaceutical Technology

JANUARY 26, 2024

Renalys plans to start a registrational trial for sparsentan as a treatment for IgA nephropathy in Japan in Q2 2024.

Licensing 147

Licensing Licensing Trials 147

Pharmaceutical Technology

MARCH 23, 2023

This year, Biohaven is expecting to advance the TYK2/JAK1 inhibitor into a Phase I trial. It showed high selectivity over JAK2, JAK3 and other kinases, and potentially improved safety over less selective or non-selective JAK inhibitors. BHV-8000’s mechanistic proof of concept was showed in several pre-clinical models.

Licensing 263

Licensing Licensing Clinical Development Development 263

Pharmaceutical Technology

JULY 28, 2022

According to the deal, Cidara will continue to oversee the international Phase III ReSPECT prophylaxis clinical trial underway. The post Melinta and Cidara sign licensing deal for rezafungin appeared first on Pharmaceutical Technology. At the time points mentioned in the deal, the NDA will be transferred to Melinta. “We

Licensing 147

Licensing Licensing Clinical Trials Clinical Trials 147

Pharmaceutical Technology

OCTOBER 4, 2022

In the Phase III portion of a Phase II/III clinical trial in Asia, ensitrelvir met the primary endpoint. The post Shionogi and MPP enter Covid-19 antiviral licensing deal appeared first on Pharmaceutical Technology.

Licensing 147

Licensing Licensing Manufacturing Medicine 147

Pharmaceutical Commerce

FEBRUARY 20, 2024

The agency will make its final decision surrounding the locally advanced or metastatic nonsquamous NSCLC drug —based on results from the TROPION-Lung01 Phase III trial—by Q4 2024.

Licensing 101

Licensing Licensing Trials Drugs 101

pharmaphorum

APRIL 22, 2021

Biosensor firm physIQ has licensed its technology to Johnson & Johnson’s Janssen pharma unit in a multi-year deal, to investigate use of wearable sensors in virtual clinical trials. The poll of 114 triallists by clinical data specialist ERT found 82% of them found organisations aery using “virtual trial” approaches.

Licensing 72

Licensing Licensing Trials Clinical Trials 72

pharmaphorum

JANUARY 9, 2023

Swiss biotech Stalicla has continued to diversify its pipeline from a focus on autism therapies with a deal to license Novartis’ mavoglurant, in clinical trials for cocaine use disorder (CUD) as well as neurodevelopmental disorders (NDD). STP-2 was licensed from Evgen Pharma in October last year.

Licensing 59

Licensing Licensing Trials Clinical Trials 59

Bio Pharma Dive

OCTOBER 27, 2022

GSK said the drug, formerly a top prospect licensed from German biotech Morphosys, showed “limited efficacy” in a Phase 3 study of patients with rheumatoid arthritis.

Drugs 200

Drugs Licensing Licensing Trials 200

Bio Pharma Dive

FEBRUARY 10, 2022

The agency criticized Eli Lilly for using a trial run in China to seek approval of an immunotherapy it licensed from Innovent Biologics. Outside advisers agreed in a decisive vote that could have repercussions for several other drugmakers.

Licensing 340

Licensing Licensing Drugs Trials 340

Bio Pharma Dive

DECEMBER 14, 2021

Fitusiran, which Sanofi licensed from Alnylam, could finally get to market after trial delays and safety concerns slowed its progress. But gene therapies and other new medicines might provide competition.

Gene Therapy 323

Gene Therapy Licensing Licensing Gene 323

Pharmaceutical Technology

MAY 18, 2023

The trial, a six-week study, will assess the change in the Hamilton Depression Rating Scale score, says Houghtaling. The trial will take place at US clinical sites, adds Houghtaling. Gate Neuroscience has already identified the CRO for the trial alongside some initial trial sites, he says. Rob Houghtaling, Sr.

Trials 130

Trials Licensing Licensing Development 130

Pharma Times

DECEMBER 21, 2021

The DETERMINE trial aims to discover whether existing ‘licensed’ drugs could also benefit patients with rare cancer types that the drug is not currently licensed for.

Trials 115

Trials Licensing Licensing Drugs 115

pharmaphorum

NOVEMBER 15, 2022

Lantheus’ pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma. The post Lantheus on POINT in radio-oncology with $2bn licensing deal appeared first on. Lantheus is promising up to $1.8 billion in milestone payments.

Licensing 52

Licensing Licensing FDA Approval Trials 52

BioTech 365

JANUARY 10, 2022

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials • Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN® … Continue reading →

Clinical Trials 40

Clinical Trials Clinical Trials Licensing Licensing 40

Drug Discovery World

NOVEMBER 24, 2023

Project leader, Associate Professor Keith Chappell, said the preliminary clinical trial results were an ‘exciting reward’ for the team’s continued dedication and the community’s widespread support for the project. “We The Clamp2 trial group showed a 2.5-fold fold boost in neutralising ‘titres’ and it was 2.1 in the Novavax group.

Clinical Trials 110

Clinical Trials Clinical Trials Engineer Vaccination 110

Drug Discovery World

DECEMBER 7, 2023

A potential schizophrenia treatment, discovered at Vanderbilt University in Tennessee in the US, has been cleared by the US Food and Drug Administration for use in Phase I clinical trials. The post Potentially game-changing schizophrenia drug enters Phase I trials appeared first on Drug Discovery World (DDW).

Trials 119

Trials Drugs Clinical Trials Clinical Trials 119

Pharmaceutical Technology

APRIL 19, 2023

Neuronascent plans to start a potential Phase II trial of its neurorestorative agent NNI-362 in Parkinson’s disease in H1 2024, said CEO Judith Kelleher-Andersson in an interview with P harmaceutical Technology. The potential Phase II trial in Parkinson’s disease will recruit between 75 and 100 patients, said Kelleher-Andersson.

Trials 130

Trials Drugs Licensing Licensing 130

BioTech 365

JANUARY 19, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Ex-Gilead execs bag $80M to trial drug licensed from Merck KGaA.Ex-Gilead Gilead execs bag $80M to trial drug licensed from Merck KGaA ntaylor Tue, 01/19/2021 – 08:16 from … Continue reading →

Licensing 40

Licensing Licensing Trials Drugs 40

Fierce Pharma

AUGUST 23, 2023

On Wednesday, GSK left little doubt about the benefit of Shingrix as it reported 100% efficacy from a post-licensing trial of the shot.

Vaccination 83

Vaccination Vaccine Trials Licensing 83

BioTech 365

JANUARY 27, 2022

Systemic Hypertension Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, Licensing and Acquisitions, and Drug-specific Revenue Forecasts – ResearchAndMarkets.com Systemic Hypertension Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, Licensing (..)

Clinical Trials 40

Clinical Trials Clinical Trials Licensing Licensing 40

BioTech 365

JANUARY 27, 2022

Glioblastoma (GBM) Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, Licensing and Acquisitions, and Drug-specific Revenue Forecasts – ResearchAndMarkets.com Glioblastoma (GBM) Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, Licensing and (..)

Clinical Trials 40

Clinical Trials Clinical Trials Licensing Licensing 40

BioTech 365

JANUARY 27, 2022

Atrial Fibrillation (AF) Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, Licensing and Acquisitions, and Drug-Specific Revenue Forecasts – ResearchAndMarkets.com Atrial Fibrillation (AF) Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, (..)

Clinical Trials 40

Clinical Trials Clinical Trials Licensing Licensing 40

pharmaphorum

JULY 8, 2022

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last year – in Europe and other international markets. The post Sobi bolsters blood division via $435m ADC licensing deal appeared first on.

Licensing 52

Licensing Licensing Sales Marketing 52

Rethinking Clinical Trials

JULY 6, 2023

Over the past several years, a variety of factors have accelerated the need for decentralized trials, including the push to make trials more accessible, the increased speed of science, the possibility of environmentally conscious trials, and the need to be flexible in a rapidly changing world.

Trials 130

Trials Clinical Trials Clinical Trials Licensing 130

BioTech 365

JANUARY 27, 2022

Systemic Lupus Erythematosus (SLE)Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, Licensing and Acquisitions, and Drug-specific Revenue Forecasts – ResearchAndMarkets.com Systemic Lupus Erythematosus (SLE)Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, (..)

Clinical Trials 40

Clinical Trials Clinical Trials Licensing Licensing 40

Drug Discovery World

JANUARY 16, 2024

The Jenner Institute at the University of Oxford is conducting the study using Bacille Calmette-Guérin (BCG), the current licensed vaccine against TB. The post Clinical trial will test novel inhaled TB vaccine appeared first on Drug Discovery World (DDW).

Clinical Trials 59

Clinical Trials Clinical Trials Vaccination Vaccine 59

Fierce Pharma

AUGUST 3, 2023

Bristol Myers Squibb and BeiGene have settled their Abraxane feud by terminating their three-drug licensing deal altogether. Bristol Myers Squibb and BeiGene decided to terminate their three-drug licensing deal. Sumitomo Pharma's Otsuka-partnered schizophrenia candidate ulotaront failed in two phase 3 trials.

Trials 52

Trials Licensing Licensing Drugs 52

Cloudbyz

MAY 11, 2023

Clinical trials play a vital role in bringing new therapies and treatments to patients, but they can be expensive and resource-intensive endeavors. Understanding the factors driving clinical trial costs is essential for researchers, sponsors, and other stakeholders involved in the drug development process.

Clinical Trials 92

Clinical Trials Clinical Trials Trials Compliance 92

XTalks

JULY 6, 2022

The adoption of decentralized clinical trial models has gained significant momentum in the past several years, even before the COVID-19 pandemic that triggered the need for more remote options to mitigate trial disruptions. Rachel Colite, VP Decentralized Clinical Trials, Cogstate.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Licensing 98

pharmaphorum

APRIL 14, 2022

The drugmaker has reported top-line results from the phase 1/2 EPCORE trial of epcoritamab as a third-line therapy for relapsed/refractory LBCL, revealing an overall response rate of 63% and a median duration of response of 12 months. The post AbbVie preps filings for lymphoma bispecific licensed from Genmab appeared first on.

Licensing 64

Licensing Licensing Immune Response Antibody 64

BioTech 365

OCTOBER 14, 2021

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase … Continue reading → (..)

Licensing 52

Licensing Licensing Clinical Trials Clinical Trials 52

pharmaphorum

AUGUST 18, 2021

Akili already has the first and only FDA cleared video game-based digital therapeutic (DTx) for children with attention-deficit hyperactivity disorder (ADHD), but is looking to add to its range via a licensing deal with Australia’s TALi Digital. . Akili is one of a group of companies that were founded by PureTech, which retains a stake.

Licensing 64

Licensing Licensing Sales FDA Approval 64

The Pharma Data

AUGUST 5, 2020

AstraZeneca has signed a licensing deal with UK-based biotech company Redx Pharma for its fibrotic disease candidate RXC006. Following the out licensing agreement, AZ will take RXC006 into clinical development, and will focus on evaluating the asset in a number of fibrotic disease including IPF. Source link.

Licensing 52

Licensing Licensing Clinical Trials Clinical Trials 52

BioTech 365

JUNE 9, 2021

World Pancreatic Cancer Market Spotlight 2021-2031: Key Marketed and Pipeline Drugs, Events, Clinical Trials, Regulations, Disease Prevalence, Licensing and Acquisition, Revenue – ResearchAndMarkets.com World Pancreatic Cancer Market Spotlight 2021-2031: Key Marketed and Pipeline Drugs, Events, Clinical Trials, Regulations, Disease Prevalence, (..)

Clinical Trials 40

Clinical Trials Clinical Trials Regulation Licensing 40